Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
Compared with sorafenib, tivozanib was associated with improved progression-free survival and objective response rate, researchers reported.
Renal Cell Carcinoma News
RENAL CELL CARCINOMA ADVISOR
Renal Cell Carcinoma News
First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
About 25% of patients with previously untreated advanced non-clear cell renal cell carcinoma had an objective response to pembrolizumab.
Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma
New analysis shows that early tumor shrinkage with cabozantinib is associated with longer survival compared with everolimus.
Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma
Avelumab-axitinib regimen offers better progression-free survival and responses than sunitinib for patients with previously untreated advanced RCC, regardless of risk group or PD-L1 status.
Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed
Patients with treatment-naive, intermediate- and poor-risk advanced RCC continue to have superior overall survival with the dual ICI regimen compared with sunitinib alone.
Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
As first-line therapy for locally advanced or metastatic renal cell carcinoma, pembrolizumab plus axitinib offers longer overall and progression-free survival compared with sunitinib.
The Incidence of Some Obesity-Related Cancers Is Increasing Among Young Adults
Obesity in childhood and adolescence may be related to the disproportionate rise in certain obesity-related cancers in younger adults, according to authors.
Benign Pathology After Partial Nephrectomy More Common Than Thought
New study finds a prevalence of benign pathologic findings after PN of 30.9%.
Karyopherin a2 May Be Prognostic Indicator in Renal Cell Carcinoma
Researchers theorize that KPNA2 expression could be used in the future to stratify risk groups among patients with renal cell carcinoma (RCC).
Changes in Renal Cell Carcinoma Pathologic Staging and Histologic Grading
A review article examines the challenges in pathologic staging and grade reporting for patients with renal cell carcinoma.
VEGF-TKI Adjuvant Trial Results in Renal Cell Carcinoma Highlight Controversy in Treatment Strategy
Insights into controversial results of trials evaluating adjuvant vascular endothelial growth factor tyrosine kinase inhibitors in high-risk renal cell carcinoma.
Cabozantinib Effective Regardless of PD-L1 Expression in RCC
PD-L1 tumor expression was found not to be a predictive biomarker for cabozantinib efficacy in mRCC.
Analysis Supports Flat Dose of Nivolumab 480 mg Every 4 Weeks
A flat-dosing schedule of nivolumab (480 mg every 4 weeks) showed pharmacologic activity and safety similar to other schedules.
Robotic Tumor Enucleation Appears Safe for Sporadic Renal Cell Carcinoma
Long-term oncologic outcomes of patients with sporadic RCC who underwent robotic tumor enucleation suggest the procedure is safe.
Drug Targeting ENPP3 Is Active in Heavily Pretreated, Advanced Metastatic RCC
An antibody-drug conjugate targeting ectonucleotide pyrophosphatase/phosphodiesterase 3 conjugated to monomethyl auristatin F had some antitumor activity in patients with advanced, metastatic renal cell carcinoma.
Adjuvant Sunitinib in Renal Cell Carcinoma May Increase Symptoms, Reduce Health Quality Scores
When sunitinib was given as an adjuvant therapy in renal cell carcinoma, patients reported worse symptoms and lower health-related quality of life scores.
Stereotactic Body Radiation Therapy May Improve Localized Control in Oligometastatic RCC
Stereotactic body radiation therapy (SBRT) may be a safe and effective therapeutic option that couold provide localized control.
Systemic Therapy Post-Radiosurgery in RCC May Not Affect Outcomes
The impact of switching to or continuing treatment with systemic therapy post-stereotactic radiosurgery in renal cell carcinoma requires further study.
Biomarkers May Predict Patient Response to Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma
Circulating blood biomarkers related to angiogenesis may help clinicians predict who will have a robust response to sunitinib.
A High Level of Circulating Vitamin D Protein Is Associated With a Decreased Risk of Kidney Cancer
Research focused on renal cell carcinoma appears to confirm the potential etiologic role of vitamin D binding protein in cancer.
Want to read more?
Please login or register first to view this content.
